The exclusive license "secures Abiomed’s rights to the technology and gives Abiomed the right to manufacture the sensors," according to a press release.
The exclusive agreement extends an existing deal the 2 companies 1st struck in 2010, according to a press release.
"Abiomed is committed to providing continuous enhancements to our Impella platform to help our customers strive to achieve optimal patient outcomes," chairman, president & CEO Michael Minogue said in prepared remarks. "This exclusive licensing agreement between the Opsens and Impella technologies offers the ability to understand the role of myocardial unloading and wall tension, as well as the impact of recovery under a future ‘smart’ pumping algorithm."
Earlier this month Abiomed won CE Mark approval in the European Union for its Impella RP right-side cardiac assist device. Last week the company escaped a shareholders’ lawsuit filed over its alleged off-label marketing for the Impella 2.5 device.